Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

The Diagnostic Journey and Ruling Out Mimics

At a Glance

There is no single test for CIDP, so doctors diagnose it using clinical exams, electrical nerve tests, and supportive evidence like spinal taps. A crucial step is ruling out "mimics" like POEMS syndrome or diabetic neuropathy, which look similar but require completely different treatments.

Diagnosing CIDP is often a process of exclusion. Because there is no single “blood test” that can definitively confirm CIDP, doctors use a combination of clinical exams, electrical testing, and specialized imaging to build a case. Most importantly, they must rule out “mimics”—conditions that look like CIDP but require very different treatments [1][2].

The 2021 Diagnostic Framework

Current guidelines from the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) have simplified how doctors talk about diagnostic certainty. They now use two main categories [1][2]:

  • CIDP: Your clinical symptoms and electrical tests (EMG/NCS) clearly show the pattern of immune-mediated nerve damage [1].
  • Possible CIDP: Your symptoms suggest CIDP, but the electrical tests are not yet “definite.” In this case, doctors look for Supportive Evidence to confirm the diagnosis [2].

Moving from “Possible” to “Definite”

If you are in the “Possible” category, your care team may use several supportive tools to find the proof they need [2][3]:

  1. Cerebrospinal Fluid (CSF) Analysis: A lumbar puncture (spinal tap) may show elevated protein without an increase in white blood cells, a classic sign of CIDP known as “albuminocytologic dissociation” [4].
  2. Nerve Ultrasound or MRI: These scans look for nerve hypertrophy (swelling) in the roots of the spine or main nerve trunks [5][6].
  3. Objective Treatment Response: Sometimes, the best “test” is starting treatment. If you show a clear, measurable improvement in strength or function after a trial of IVIG or steroids, it supports the diagnosis [7][8].

Identifying the Mimics

It is vital to distinguish CIDP from other conditions, as some “mimics” can be dangerous if misdiagnosed [9].

POEMS Syndrome

POEMS is a rare multisystem disorder that is often mistaken for CIDP because it also causes nerve damage. However, it requires an entirely different treatment (often chemotherapy or stem cell transplant) [10][11].

  • Red Flags for POEMS: Significant swelling in the legs, unexplained skin darkening or red spots, enlarged organs (like the liver or spleen), and high levels of a protein called VEGF in the blood [12][13].

Diabetic Polyneuropathy

Many people with CIDP also have diabetes. While diabetic neuropathy is common, it usually affects only the longest nerves (feet first) and doesn’t respond to immune therapy [14]. If a person with diabetes has weakness in their shoulders or hips (proximal weakness), doctors should suspect CIDP [14].

Anti-MAG and GBS

  • Anti-MAG Neuropathy: Often presents with a very specific “tremor” in the hands and is confirmed with a blood test for Anti-MAG antibodies [15].
  • Guillain-Barré Syndrome (GBS): GBS is the “acute” cousin of CIDP. It comes on very quickly (days to weeks), whereas CIDP is a slow, chronic progression over 8 weeks or more [16][17].

Hereditary Neuropathies (Charcot-Marie-Tooth)

Conditions like Charcot-Marie-Tooth (CMT) disease are genetic and can look similar to CIDP on nerve conduction studies, but they do not respond to immune therapies [18]. Genetic testing and a detailed family history help distinguish these from CIDP.

Your diagnostic journey is about finding the right “lock” for the “key” of treatment. By ruling out these mimics, your doctor ensures you are receiving the therapy that will actually help you heal [1].

Common questions in this guide

What is the difference between definite and possible CIDP?
Doctors use clear electrical test (EMG/NCS) results to diagnose definite CIDP. If your tests are borderline but symptoms strongly match, you may have possible CIDP and will need supportive tests like a spinal tap or ultrasound to confirm the diagnosis.
What tests will I need if I have 'possible' CIDP?
If your initial electrical tests do not provide a definitive answer, your care team may use supportive tests to gather more evidence. These include a spinal tap to look for elevated protein, an ultrasound or MRI to check for swollen nerves, or a trial of IVIG treatment to see if your symptoms improve.
What are CIDP mimics?
CIDP mimics are other nerve conditions that cause similar symptoms but require completely different treatments. Common mimics include POEMS syndrome, diabetic polyneuropathy, Anti-MAG neuropathy, and Guillain-Barré Syndrome (GBS).
How can doctors tell the difference between CIDP and diabetic neuropathy?
While both cause nerve damage, diabetic neuropathy typically starts in the longest nerves, affecting the feet first. If a patient with diabetes develops weakness in their shoulders or hips, neurologists will suspect CIDP instead.
Why might my doctor start an IVIG treatment trial before my diagnosis is official?
Sometimes the best way to confirm a possible CIDP diagnosis is to see how your body responds to therapy. If your strength and daily function clearly improve after a trial of IVIG or steroids, it provides strong supportive evidence that you have CIDP.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my EMG/NCS results, do I meet the criteria for 'CIDP' or 'Possible CIDP'?
  2. 2.If I am currently classified as 'Possible,' which supportive tests (like CSF protein or nerve ultrasound) do we need to perform next?
  3. 3.Have we checked my VEGF levels and screened for monoclonal proteins (M-spike) to rule out POEMS syndrome?
  4. 4.How do we distinguish my symptoms from diabetic neuropathy, given my medical history?
  5. 5.If we start a trial of IVIG, how will we objectively measure my 'treatment response' to confirm the diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

    Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

    European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

    PMID: 34327760
  2. 2

    Tips in navigating the diagnostic complexities of chronic inflammatory demyelinating polyradiculoneuropathy.

    Lewis RA, van Doorn PA, Sommer C

    Journal of the neurological sciences 2022; (443()):120478 doi:10.1016/j.jns.2022.120478.

    PMID: 36368137
  3. 3

    European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

    Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

    Journal of the peripheral nervous system : JPNS 2021; (26(3)):242-268 doi:10.1111/jns.12455.

    PMID: 34085743
  4. 4

    Diagnostic usefulness of plexus magnetic resonance imaging in chronic inflammatory demyelinating polyradiculopathy without electrodiagnostic criteria of demyelination.

    Fargeot G, Viala K, Theaudin M, et al.

    European journal of neurology 2019; (26(4)):631-638 doi:10.1111/ene.13868.

    PMID: 30431216
  5. 5

    Role of Imaging in Chronic Inflammatory Demyelinating Polyneuropathy: A Systematic Review.

    Tozza S, Cassano E, Erra C, et al.

    European journal of neurology 2025; (32(6)):e70226 doi:10.1111/ene.70226.

    PMID: 40452261
  6. 6

    MRI quantifies lumbosacral nerve root and sciatic nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy.

    Shah S, Morrow JM, Sinclair CDJ, et al.

    European journal of radiology 2020; (130()):109164 doi:10.1016/j.ejrad.2020.109164.

    PMID: 32688240
  7. 7

    RELEVANCE OF DIAGNOSTIC INVESTIGATIONS IN CHRONIC INFLAMMATORY DEMYELINATING POLIRADICULONEUROPATHY: DATA FROM THE ITALIAN CIDP DATABASE.

    Liberatore G, Manganelli F, Cocito D, et al.

    Journal of the peripheral nervous system : JPNS 2020; doi:10.1111/jns.12378.

    PMID: 32343015
  8. 8

    Chronic inflammatory demyelinating polyradiculoneuropathy: Diagnostic problems in clinical practice in Serbia.

    Basta I, Delic N, Gunjic I, et al.

    Journal of the peripheral nervous system : JPNS 2023; (28(2)):226-236 doi:10.1111/jns.12537.

    PMID: 36738239
  9. 9

    Distinguishing Chronic Inflammatory Demyelinating Polyneuropathy From Mimic Disorders: The Role of Statistical Modeling.

    Swart G, Skolka MP, Shelly S, et al.

    Journal of the peripheral nervous system : JPNS 2025; (30(1)):e12682 doi:10.1111/jns.12682.

    PMID: 39801067
  10. 10

    Thrombocytosis distinguishes POEMS syndrome from chronic inflammatory demyelinating polyneuropathy.

    Naddaf E, Dispenzieri A, Mandrekar J, Mauermann ML

    Muscle & nerve 2015; (52(4)):658-9 doi:10.1002/mus.24768.

    PMID: 26179010
  11. 11

    POEMS Syndrome Without a Detectable Monoclonal Peak: The Critical Role of VEGF and Bone Marrow Biopsy in Diagnosis.

    J Pecorin P, A MM, Olson G, et al.

    Case reports in hematology 2025; (2025()):5530850 doi:10.1155/crh/5530850.

    PMID: 41018683
  12. 12

    POEMS syndrome: clinical update.

    Brown R, Ginsberg L

    Journal of neurology 2019; (266(1)):268-277 doi:10.1007/s00415-018-9110-6.

    PMID: 30498913
  13. 13

    POEMS syndrome presenting with Vibrio vulnificus-like cutaneous lesions: a CARE guidelines-compliant case report.

    Li X, Lin B, Lin L, Song C

    Frontiers in medicine 2025; (12()):1625877 doi:10.3389/fmed.2025.1625877.

    PMID: 40697923
  14. 14

    Atypical diabetic neuropathies.

    McCray BA, Stino AM, Davalos L, et al.

    BMJ (Clinical research ed.) 2025; (390()):e081109 doi:10.1136/bmj-2024-081109.

    PMID: 41022466
  15. 15

    Paraproteinemia and neuropathy.

    Koike H, Katsuno M

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(11)):4489-4501 doi:10.1007/s10072-021-05583-7.

    PMID: 34529193
  16. 16

    Peripheral Nervous System (PNS) Myelin Diseases.

    Scherer SS, Svaren J

    Cold Spring Harbor perspectives in biology 2024; (16(5)) doi:10.1101/cshperspect.a041376.

    PMID: 38253417
  17. 17

    Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications.

    Dziadkowiak E, Nowakowska-Kotas M, Rałowska-Gmoch W, et al.

    International journal of molecular sciences 2023; (24(11)) doi:10.3390/ijms24119180.

    PMID: 37298132
  18. 18

    Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy.

    Eftimov F, Lucke IM, Querol LA, et al.

    Brain : a journal of neurology 2020; (143(11)):3214-3224 doi:10.1093/brain/awaa265.

    PMID: 33155018

This page explains the CIDP diagnostic process for educational purposes only. Only a qualified neurologist can formally diagnose CIDP or rule out similar mimic conditions based on your specific clinical tests and medical history.

Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.